BRAF and colorectal cancer: Is the use of doublet therapy (encorafenib and cetuximab) compared with standard chemotherapy (with cetuximab and irinotecan-based regimens) a cost-effective treatment strategy in patients with metastatic BRAF variant colorectal cancer?